Discrimination of the chemotherapy resistance status of human leukemia and glioblastoma cell lines by MALDI-TOF-MS profiling

Author:

Ledesma Martín1,Poodts Daniela2,Amoia Sofía2,Hajos Silvia3,Fundia Ariela4,Vay Carlos5,Pibuel Matías3,Lompardía Silvina3

Affiliation:

1. Hospital del Bicentenario de Esteban Echeverría

2. Universidad de Buenos Aires (UBA)

3. Instituto de Estudios de la Inmunidad Humoral (IDEHU), UBA-Consejo Nacional de Investigaciones Científicas Y Técnicas (CONICET)

4. Instituto de Medicina Experimental (IMEX)-CONICET, Academia Nacional de Medicina

5. Hospital de Clínicas "José de San Martín", UBA

Abstract

Abstract Chemotherapy mistreatment is partially due to a lack of rapid and reliable tools to discriminate between sensitive and resistant phenotypes. In many cases, the resistance mechanism is not fully understood, impacting diagnostic tools' absence. This work aims to determine the capacity of MALDI-TOF-MS profiling to discriminate between chemotherapy-resistant and sensitive phenotypes in leukemia and glioblastoma cells. A multivariate analysis of two therapy-resistant leukemia cell lines (Ki562 and Kv562) and two TMZ-resistant glioblastoma cell lines (U251R and LN229R) and their sensitive counterparts was performed. In this work, we first show MALDI-TOF-MS patterns analysis's ability to differentiate these cancer cell lines by their chemotherapy-resistant status. We present a rapid and inexpensive tool that would guide and complement the therapeutic decision.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3